Kane Biotech Inc. KNBIF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 28.40K | 42.70K | 298.60K | 403.70K | 1.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.40K | 42.70K | 298.60K | 403.70K | 1.34M |
| Cost of Revenue | 28.40K | 76.70K | 300.30K | 473.10K | 994.00K |
| Gross Profit | -100.00 | -34.00K | -1.60K | -69.30K | 344.10K |
| SG&A Expenses | 1.47M | 1.09M | 1.41M | 1.27M | 1.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.93M | 1.58M | 2.15M | 2.39M | 3.38M |
| Operating Income | -1.90M | -1.54M | -1.85M | -1.99M | -2.04M |
| Income Before Tax | -2.03M | -1.68M | -2.01M | -2.32M | -2.37M |
| Income Tax Expenses | -71.60K | -74.40K | -77.50K | -936.00K | -936.00K |
| Earnings from Continuing Operations | -1.96 | -1.61 | -1.93 | -1.38 | -1.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -936.00K | -882.60K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.96M | -1.61M | -1.93M | -2.32M | -2.32M |
| EBIT | -1.90M | -1.54M | -1.85M | -1.99M | -2.04M |
| EBITDA | -1.80M | -1.41M | -1.71M | -1.82M | -1.91M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 785.98M | 859.32M | 799.31M | 722.48M | 526.94M |
| Average Diluted Shares Outstanding | 785.98M | 859.32M | 799.31M | 722.48M | 526.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |